Rani Therapeutics Holdings (RANI) Non-Current Debt (2020 - 2025)

Rani Therapeutics Holdings has reported Non-Current Debt for 5 years, with the latest figure at $2.2 million in Q2 2025.

• On a quarterly basis, Non-Current Debt fell 87.05% year-over-year to $2.2 million in Q2 2025; TTM through Jun 2025 was $2.2 million, a 87.05% decrease from a year earlier, with the FY2024 full-year figure at $9.6 million, down 60.74% from the prior year.
• Non-Current Debt was $2.2 million for Q2 2025 at Rani Therapeutics Holdings, down from $5.9 million in the prior quarter.
• The five-year high for Non-Current Debt was $29.3 million in Q2 2023, with the low at $2.2 million in Q2 2025.
• Average Non-Current Debt over 4 years is $18.6 million, with a median of $19.0 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Non-Current Debt surged 99.43% in 2023, then plunged 87.05% in 2025.
• Over 4 years, Non-Current Debt stood at $29.1 million in 2022, then dropped by 16.0% to $24.5 million in 2023, then sank by 60.74% to $9.6 million in 2024, then plunged by 76.81% to $2.2 million in 2025.
• The last three Non-Current Debt figures came in at $2.2 million (Q2 2025), $5.9 million (Q1 2025), and $9.6 million (Q4 2024), per Business Quant data.